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Abstract 
Background: African Americans (AA) have a higher prevalence of Trichomonas vaginalis (Tv) infection and a higher 
prostate (PC) risk. Past studies suggest an association between Tv seropositivity and PC, and therefore we prospec-
tively investigated this association among AA men.
Results: Incident PC cases were individually matched to controls in a nested case–control study within the Southern 
Community Cohort Study (SCCS). Primary analysis included 296 PC cases and 497 race-matched controls. Levels of Tv 
antibody response were measured by ELISA in serum collected at baseline. Tv antibody response did not significantly 
differ between cases and controls overall or within AA participants (253 AA cases). There were no significant associa-
tions or trends between levels of Tv response and PC risk or the diagnosis of aggressive PC.
Conclusion: We found no evidence of a prospective association between baseline Tv infection and PC risk in AA 
men. Tv infection in men may have substantial health implications in HIV transmission and reproductive outcomes, 
but may not impact future PC risk in AA men at high-risk for PC. Further efforts need to define past vs. present Tv 
infection and to separate pathophysiology from PC detection.
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Background
Trichomonas vaginalis (Tv) is a sexually transmitted pro-
tozoan parasite. In men, urethral infection may ascend to 
the prostatic urethra and glandular tissue. With asymp-
tomatic infection common, Tv exposure may induce a 
sustained inflammatory response to advance prostate 
carcinogenesis [1]. Analysis of the Health Professionals 
Follow-up Study and the Physicians Health Study found 
that Tv antibody seropositivity was significantly asso-
ciated with prostate cancer (PC) risk [2, 3] or PC death 
[2]. In contrast, Tv seropositivity was not associated with 
PC risk in the Prostate Cancer Prevention Trial (PCPT) 
[4] or a population-based case–control analysis [5]. The 
purpose of this study was to determine the prospective 
relationship between Tv infection and PC risk among 
African American (AA) men. Past studies included few 
AA men, although there are data suggesting the preva-
lence of Tv infection and the risk of PC may be greater 
than among white men [6].
Methods
Details of the Southern Community Cohort Study 
(SCCS) have been published [7]. Incident PC cases 
among nearly 35,000 male participants enrolled at age 
40–79 during 2002–2009 were identified through link-
ages through 2013 with state tumor registries and the 
National Death Index. All participants provided writ-
ten informed consent, and all protocols were approved 
by Institutional Review Boards at Vanderbilt University 
and Meharry Medical College. All SCCS data can be 
requested through an online request (southerncommu-
nitystudy.org). The request will be reviewed by the SCCS 
Data and Biospecimen Use Committee to ensure that it is 
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scientifically justified and that participant confidentiality 
is preserved. Two controls per case were selected by inci-
dence density sampling and were individually matched 
by age (5 years), race (self-reported black or white), site, 
and time of donation of blood samples at study entry. A 
blood sample was collected at baseline recruitment, and 
serum was frozen-stored at −80  °C. Serum was assayed 
in duplicate for antibodies against Tv by ELISA to detect 
the IgG antibodies against the purified recombinant Tv 
α-actinin protein and assessed spectrophotometrically 
[8]. We previously assigned scores from 0 to 4+ to serum 
based on the calculation of P/N values obtained using 
the protein ACT-P2 as the target [2–4, 8]. For this study, 
cutoff points for seropositivity were obtained by dividing 
the average OD405nm of the seropositive control serum by 
the corresponding seronegative control serum. The low-
est seronegative control was assigned a score of 0 (zero). 
Values from 0 to the next lowest was given a score of 1+, 
and subsequent scores of 2+, 3+, and 4+ were assigned 
similarly as values increased. The sera with P/N scores 
≤2 were negative as evidenced by lack of detection of any 
T. vaginalis proteins by immunoblot [8]. Scores ≥3 were 
positive and had antibody to α-actinin and other tricho-
monad proteins [8]. We used conditional logistic regres-
sion to compute odds ratios (OR) and 95  % confidence 
intervals while controlling for household income. Cancer 
stage or Gleason score from state tumor registries pro-
viding these data were also analyzed after controlling for 
age, race, and income.
Results
The majority of the study population was over 60  years 
of age at recruitment (n  =  549, 62  %), and reported a 
household income less than $15,000/year (n = 512, 58 %). 
Approximately 85  % of the study population was AA. 
Table 1 summarizes the association between Tv seroposi-
tive status and PC. Mean antibody response levels were 
Table 1 Trichomonas vaginalis and  association with  pros-
tate cancer risk
Adjusted for age at diagnosis, race, income
a Adjusted for age at diagnosis and income*
T. vaginalis Cases Controls OR 95 % CI
n 296 585
Mean (SD) 0.26 (0.11) 0.26 (0.11)
Serostatus
 Negative 227 (76.7 %) 461 (78.8 %) 1.0 Ref
 Positive 69 (23.3 %) 124 (21.2 %) 1.11 0.77–1.61
Score
  0 60 (20.3 %) 132 (22.6 %) 1.0 Ref
  1 95 (32.1 %) 168 (28.7 %) 1.18 0.77, 1.82
  2 72 (24.3 %) 161 (27.5 %) 0.94 0.58–1.53
  3 50 (16.9 %) 84 (14.4 %) 1.25 0.74–2.11
  4+ 19 (6.4 %) 40 (6.8 %) 0.98 0.48–1.97
African Americans Onlya
n 253 497
Mean (SD) 0.26 (0.11) 0.26 (0.11)
Serostatus
 Neg 191 (75.5 %) 386 (77.7 %) 1.0 Ref
 Pos 62 (24.5 %) 111 (22.3 %) 1.12 0.76–1.66
Score
 0 50 (19.8 %) 104 (20.9 %) 1.0 Ref
 1 80 (31.6 %) 145 (29.2 %) 1.10 0.69–1.76
 2 61 (24.1 %) 137 (27.6 %) 0.87 0.51–1.47
 3 44 (17.4 %) 74 (14.9 %) 1.18 0.67–2.08
 4+ 18 (7.1 %) 37 (7.4 %) 0.95 0.45–1.97
Table 2 Trichomonas vaginalis seropositive status and diagnosis of aggressive prostate cancer
Stage and grade data were not provided by every tumor registry
a Adjusted for age at diagnosis, race, and income
Diagnosis of aggressive PCa
Gleason < 7 Gleason ≥ 7 OR 95 % CI
n 74 101
Mean (SD) 0.25 (0.10) 0.26 (0.10)
Serostatus
 Negative 60 (81.1 %) 80 (79.2 %)
 Positive 14 (18.9 %) 21 (20.8 %) 1.04 0.48–2.26
Stage 0–1 Stage 2–4
n 230 40
Mean (SD) 0.25 (0.12) 0.26 (0.10)
Serostatus
 Negative 179 (77.8 %) 30 (75.0 %)
 Positive 51 (22.2 %) 10 (25.0 %) 1.23 0.55–2.74
Page 3 of 3Fowke et al. BMC Res Notes  (2016) 9:224 
similar between cases and controls (all p  >  0.05). There 
was no significant association between Tv and PC in the 
total study population, or when restricting to AA men. 
Furthermore, Tv exposure was not associated with PC 
Gleason score of 7 or more, or stage 2–4 PC at diagnosis, 
in a case-only analysis (Table 2).
Discussion
Tv disproportionately affects minorities and low-
income populations [6]. However, unlike two past stud-
ies of predominately white professionals [2, 3], we found 
no evidence of association within AA men. A post hoc 
power calculation based on a similar matched nested 
case–control design and assuming a 25  % exposure, 
Type I error of 5 %, and 80 % power, would be able to 
detect an OR = 1.42, suggesting a sufficient sample size 
to identify a moderate association. Residual confound-
ing is unlikely to have led to a null association. As previ-
ously detailed, differences in patient characteristics and 
detection protocols could explain differences in results 
across studies [4]. Similarly, an inflammatory effect from 
Tv would likely increase PSA levels, and thus increase 
the likelihood of detecting an asymptomatic PC and 
lead to a positive association. No association between 
Tv seropositivity and PC was found in the PCPT, with 
rigorous control for PC screening including an end of 
study prostate biopsy [4]. Alternatively, analysis of the 
Prostate, Lung, Colorectal and Ovarian cancer screen-
ing trial found Tv seropositivity significantly associated 
with benign prostatic hyperplasia [9], suggesting Tv may 
exacerbate lower urinary tract symptom severity and 
possibly lead to a PC detection. [10] Tv seropositivity 
is relatively stable over time [10], limiting the ability to 
identify an etiologically relevant time of exposure. Our 
prospective analysis found no association between base-
line Tv seropositivity and future PC risk, and further 
efforts are needed to define past vs. recent Tv infection 
and to separate pathophysiology from the detection of 
PC.
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